Nesiritide for Treatment of Heart Failure Patients | CMS Coverage Update

Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for nesiritide in the treatment of heart failure patients, effective May 15, 2026. Here's what billing teams need to know before that date.

Nesiritide billing has always carried risk. This CMS nesiritide coverage policy update changes the framework billing teams use to determine when a claim will pay and when it won't. The policy does not list specific CPT or HCPCS codes in its current published form — we'll cover what that means for your charge capture below. If you bill for inpatient or outpatient heart failure management, this modification deserves your attention before May 15, 2026.

Quick-Reference Table

CMS Nesiritide Coverage Criteria and Medical Necessity Requirements 2026

Nesiritide — sold under the brand name Natrecor — is a recombinant B-type natriuretic peptide used in the short-term treatment of acutely decompensated heart failure. It's an intravenous drug, typically administered in a hospital or observation setting. And it has a complicated history with payers.

The Centers for Medicare & Medicaid Services has scrutinized nesiritide reimbursement for years. The drug's clinical controversy — specifically, concerns raised in the mid-2000s about renal function and mortality — made it a prime target for coverage policy restrictions. This 2026 modification continues that pattern.

Because the published policy does not provide granular detail in the summary data available at this time, billing teams should pull the full policy document directly from the CMS source. Access it at https://app.payerpolicy.org/p/cms/311-v1. What we can say with confidence: coverage policy for nesiritide has always hinged on medical necessity criteria tied to the severity of the patient's decompensation and the appropriateness of the treatment setting.

What Medical Necessity Typically Requires for Nesiritide Coverage

CMS medical necessity standards for nesiritide have historically required documentation of acutely decompensated congestive heart failure. That means the patient's chart must show more than a chronic, stable condition. You need clinical evidence of acute exacerbation — elevated filling pressures, dyspnea at rest or with minimal exertion, and hemodynamic compromise that justifies IV vasoactive therapy.

Outpatient or serial infusion use of nesiritide has been the most contested area. CMS and the broader evidence base have not supported routine outpatient use for chronic management. If your facility has been billing nesiritide in an outpatient infusion setting without airtight documentation of acute decompensation, this policy update is a direct flag for your compliance officer.

Prior authorization requirements for nesiritide vary by Medicare Administrative Contractor region. Under traditional Medicare, prior authorization is not universally required for nesiritide — but Medicare Advantage plans administered through CMS-contracted payers may impose prior auth at the plan level. Check your specific payer contracts before assuming that a Medicare fee-for-service rule applies to your MA population.

CMS Nesiritide Exclusions and Non-Covered Indications

The core non-covered use of nesiritide under CMS policy is chronic outpatient infusion therapy. This has been a firm position since CMS and clinical bodies reviewed the FUSION trials and other evidence questioning serial nesiritide infusions for chronic heart failure management.

CMS does not cover nesiritide as a long-term or maintenance therapy. A patient who receives nesiritide every few weeks for volume management in an outpatient infusion center — without acute decompensation — does not meet the standard. Claims for that scenario will face denial.

Elective or prophylactic use also falls outside the coverage policy. If the clinical rationale in your documentation reads more like "prevention of decompensation" than "treatment of acute decompensation," you're building toward a claim denial. The distinction sounds subtle, but CMS reviewers and Medicare Administrative Contractor auditors are trained to catch it.

Coverage Indications at a Glance

Because the current policy data does not include an itemized list of indications with code-level detail, this table reflects the historically documented coverage framework for nesiritide under CMS policy. Pull the full policy document to confirm any changes to these positions in the 2026 modification.

CMS Nesiritide Billing Guidelines and Action Items 2026

Here's what your billing team and revenue cycle leadership should do right now.

CPT, HCPCS, and ICD-10 Codes for Nesiritide Under CMS Policy

The current policy data does not list specific CPT, HCPCS, or ICD-10 codes. This is worth flagging, because nesiritide billing does involve specific drug administration codes and diagnosis codes in practice — and their absence from the published policy summary does not mean they're irrelevant to your billing workflows.

What this means for your team: Do not assume the absence of code-level data means the policy has no code-level implications. Pull the full policy from CMS directly. Confirm with your Medicare Administrative Contractor which HCPCS drug codes (typically J-codes for intravenous pharmaceuticals) and which ICD-10-CM diagnosis codes they expect to see paired with nesiritide claims.

For nesiritide specifically, your MAC should be your primary source for current J-code status and any local coverage determination that applies in your region. LCD-level rules from your MAC can be more specific — and more restrictive — than the national CMS policy. If your billing team isn't already checking LCDs alongside national coverage policies, this is a good reminder to build that into your workflow.

Do not invent or assume codes based on historical billing without verifying against the current policy document. Using the wrong HCPCS code — or pairing a nesiritide claim with a diagnosis code that doesn't reflect acute decompensation — is a direct path to claim denial and potential recoupment.